Overview

Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients

Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on cardiac remodeling, as well as safety in patients with chronic heart failure.
Phase:
Phase 3
Details
Lead Sponsor:
Zensun Sci. & Tech. Co., Ltd.